drugset
drugset / Trial / NCT02902523

Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers

NCT02902523 ↗

Phase 1 Completed 50 enrolled Huons Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, single-dosing, 2x2 crossover study to compare the safety and pharmacokinetics of HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male volunteers

Timeline

Start
2016-09
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 245 mg Oral
Subject Tenofovir disoproxil fumarate Small molecule 300 mg Oral

Indications

No indication recorded.